摘要
目的探讨普瑞巴林对脑卒中后丘脑痛的疗效和安全性。方法选择该院2012年6月—2015年3月住院及门诊的脑卒中后丘脑痛患者,共96例,按随机数字表法分三组:普瑞巴林组、加巴喷丁组、卡马西平缓释片组,每组32例,三组患者分别口服普瑞巴林胶囊、加巴喷丁胶囊、卡马西平缓释片治疗,期间停用其他镇痛药物。所有患者于治疗前及治疗后1、2、4、8周进行NRS评分及睡眠障碍评分,观察三组患者的不良反应。结果普瑞巴林组在治疗后1周NRS评分下降,且在此后各个时点下降明显(P<0.05),与其他两组相比,在各个时间点差异均有统计学意义(P<0.01)。普瑞巴林组在治疗后1、2、4、8周的睡眠障碍评分与治疗前比较差异有统计学意义(P<0.05),且优于其他两组同期(P<0.01)。结论普瑞巴林可有效治疗脑卒中后丘脑痛,改善患者疼痛及睡眠障碍,不良反应少,药物耐受性良好。
Objective To study the effectiveness and safety for thalamic pain after Stroke treated with pregabalin. Methods 96 patients with thalamic pain from 2012 June to 2015 March were randomized equally into three groups:pregabalin group,gabapentin group and carbamazepine group,32 cases in each group.After managed in accordance with the Guidelines for the Secondary Prevention of Stroke,each group received respective drugs,out of other analgesic drugs during treatment. The effects were evaluated with NRS and sleep disorder score before treatment and1,2,4,8weeks,while adverse effects were observed. Results The NRS of pregabalin group decreased in each time point(P<0.05), and there was a significant difference between the three groups(P<0.01). The sleep disorder scores of pregabalin group before treatment and1,2,4,8weeks was different statistically(P<0.05),and better than the other two groups(P<0.01).Conclusion Pregabalin can improve thalamic pain and sleep disorder of patients, with little adverse effects, and is well tolerated.
出处
《中外医疗》
2015年第25期145-146,共2页
China & Foreign Medical Treatment
